human
long
search
kind
medicin
could
cure
bodi
restor
health
prolong
short
lifespan
therebi
search
pan
cure
univers
drug
could
overcom
kind
diseas
start
earli
medicin
ecumen
view
also
appear
within
tolkienian
fantasi
one
ring
power
one
would
rule
lesser
magic
ring
http
wwwtolkiencouk
unfortun
one
ring
real
life
sadli
enough
say
panacea
also
exist
least
back
realiti
review
focu
present
problem
emerg
antimicrobi
resist
mani
pathogen
bacteria
well
spread
viral
infect
discuss
impend
need
research
discoveri
novel
antimicrobi
find
altern
classic
treatment
well
use
novel
approach
provid
one
multipl
solut
tackl
human
infect
shall
also
discuss
possibl
druggabl
bacteri
ta
famili
protein
well
pro
con
approach
infecti
diseas
constitut
one
highest
caus
death
human
be
throughout
world
million
everi
year
world
health
organ
wwwwhointresearch
state
death
acut
respiratori
infect
diarrhoeal
diseas
measl
aid
malaria
account
mortal
infect
worldwid
report
total
amount
children
die
year
age
sum
million
worldwid
nearli
death
due
infecti
diseas
pneumonia
largest
singl
caus
death
underf
could
cure
prevent
proper
antibiot
treatment
figur
appli
mostli
underdevelop
countri
develop
countri
albeit
rate
mortal
much
lower
highrisk
popul
form
children
elderli
immunocompromis
peopl
gener
subject
antibiot
treatment
either
ambul
hospit
problem
much
bigger
envisag
appear
bacteria
exhibit
multi
even
pandrug
resist
falaga
karageorgopoulo
recent
epidem
outbreak
viral
infect
like
ebola
avian
influenza
middl
east
respiratori
syndrom
http
wwwcdcgovoutbreak
thu
global
figur
peopl
suffer
microbi
infect
may
reach
hundr
million
pose
huge
ethic
medic
econom
concern
must
tackl
urgent
way
one
main
problem
found
everyday
practic
treat
patient
steadi
emerg
multidrugresist
bacteria
problem
dictat
need
major
effort
discov
new
class
antimicrobi
drug
current
portfolio
compound
clinic
trial
includ
mostli
deriv
exist
antibiot
underli
resist
mechan
alreadi
exist
global
report
antimicrobi
resist
http
wwwwhointdrugresistancedocumentssurveillancereporten
scenario
particularli
worrisom
case
hospit
infect
caus
highli
resist
pathogen
although
advanc
achiev
bassetti
et
al
antibiot
resist
abr
new
conundrum
seem
ultim
denouement
temporari
regim
allevi
problem
emerg
resist
antibiot
still
use
treatment
nosocomi
infect
well
knowledg
accumul
mechan
action
antibiot
blair
et
al
urg
need
novel
infect
prevent
control
strategi
tabl
spite
fact
abr
compromis
abil
deal
infecti
diseas
recent
report
perform
uk
show
fund
devot
area
small
clearli
insuffici
head
et
al
furthermor
larg
pharmaceut
compani
stop
invest
new
antibiot
research
develop
number
industri
work
activ
discoveri
develop
program
antibacteri
agent
drop
last
year
compani
shlae
et
al
indepth
analys
food
drug
administr
fda
approv
antimicrobi
shown
number
antibacteri
attain
peak
end
decreas
fast
afterward
concomitantli
declin
pharmaceut
compani
introduc
new
molecul
antibacteri
activ
market
kinch
et
al
reason
withdraw
includ
drug
develop
time
consum
costli
process
target
discoveri
lead
compound
optim
follow
preclin
studi
final
clinic
develop
market
author
take
typic
year
thu
price
pressur
mostli
due
market
antibiot
gener
compound
sever
regulatori
hurdl
acceler
withdraw
compani
antibacteri
drug
market
turn
led
reduc
number
new
drug
approv
usfda
initi
launch
promot
develop
new
antibiot
result
far
two
new
molecul
number
new
drug
market
steadili
decreas
gener
situat
enhanc
risk
return
preantibiot
era
boucher
et
al
gloom
scenario
led
propos
reboot
fda
entir
approach
antibiot
develop
shlae
et
al
fact
action
direct
taken
design
gener
antibiot
incent
program
includ
fda
safeti
innov
act
give
fda
depart
health
human
servic
urgenc
come
list
pathogen
qualifi
drug
must
target
develop
regul
antibiot
incent
www
bioworldcom
case
antivir
discoveri
parallel
antibiot
novel
compound
frequent
introduc
market
sinc
antivir
drug
highli
specif
singl
infecti
agent
accur
diagnosi
need
antivir
prescrib
therefor
limit
number
diseas
commerci
interest
exist
effect
vaccin
vaccin
program
also
import
determin
whether
market
need
new
antivir
instanc
case
hepat
b
even
though
effect
vaccin
alreadi
exist
number
patient
alreadi
infect
still
high
constitut
signific
popul
need
antivir
therapi
due
social
econom
impact
main
effort
focus
develop
drug
human
immunodefici
viru
hiv
hepat
c
viru
hcv
infect
littler
oberg
guidelin
use
vaccin
antivir
especi
pandem
crucial
current
marketbas
system
capac
suppli
sudden
demand
vaccin
pandem
declar
stockpil
vaccin
pandem
practic
vaccin
composit
reli
respons
viru
identifi
appear
begin
pandem
situat
antivir
like
influenza
like
still
effect
prophylaxi
treatment
diseas
caus
new
pandem
viru
antivir
drug
rel
stabl
thu
stockpil
feasibl
vaccin
still
remain
primari
mode
prevent
antivir
still
role
complement
situat
http
emerg
reemerg
viral
infect
pose
seriou
problem
public
health
due
viru
dormanc
improp
diagnosi
develop
resist
antivir
furthermor
treatment
also
hamper
lack
specif
likelihood
antivir
toxic
patient
saxena
mishra
saxena
mani
altern
classic
treatment
propos
kaplan
mason
mandel
et
al
imamov
sommer
singl
drug
cure
infect
combin
differ
therapi
seem
conting
approach
especi
develop
new
antimicrobi
seem
still
far
ahead
envisag
variant
classic
altern
tabl
develop
chemic
deriv
known
antibiot
chemic
modif
activ
molecul
ii
altern
use
avail
antibiot
socal
antibiot
cycl
one
categori
antibiot
rotat
one
differ
antibiot
class
exhibit
compar
activ
although
caution
rais
approach
brown
nathwani
iii
implement
biolog
approach
like
phage
therapi
review
deresinski
new
vaccin
antimicrobi
peptid
novel
approach
includ
develop
entir
novel
class
antibiot
ii
use
new
small
molecul
antivirul
antipersist
drug
conlon
et
al
iii
employ
virul
factor
antibacteri
marra
iv
search
novel
target
alonso
et
al
find
bacteria
develop
resist
one
antibiot
may
display
greater
sensit
second
one
distinct
structur
class
phenomenon
known
collater
sensit
open
new
excit
approach
design
antibiot
treatment
imamov
sommer
furthermor
identif
virul
gene
associ
bacteri
mobilom
plasmid
bacteriophag
integr
conjug
element
ice
thrown
light
mechan
spread
abr
among
pathogen
bacteria
bacteria
abl
evolv
rapidli
adapt
new
nich
environ
wellington
et
al
clear
mobilom
joint
bacteri
respons
select
pressur
pose
human
play
central
role
arm
race
pathogen
human
thu
interest
strategi
would
worth
explor
initi
identif
inhibitor
target
transfer
dna
among
bacteria
term
conjug
inhibitor
fernandezlopez
et
al
despit
possibl
approach
develop
medium
term
everyday
practic
hospit
need
protocol
deal
infecti
outbreak
easi
reliabl
implement
therefor
addit
new
antibacteri
need
develop
translat
research
interact
among
healthcar
cadr
lead
direct
fluent
commun
research
hospit
compani
involv
drug
develop
eg
knowledg
transfer
partnership
due
time
lead
concept
druglik
approach
find
novel
bacteri
target
drug
develop
process
could
expedit
also
import
keep
mind
need
understand
biolog
bacteri
speci
aim
sinc
biolog
especi
genet
approach
signific
aid
drug
discoveri
process
trauner
sassetti
rubin
strategi
point
potenti
drug
discoveri
like
exploit
bacteri
ta
although
constitut
disput
druggabl
yet
still
compris
compel
rational
worth
explor
alonso
et
al
mutschler
meinhart
gerd
review
discuss
possibl
druggabl
ta
simpl
previous
envisag
also
term
choos
proper
toxin
combin
two
deliveri
target
mani
biolog
activ
molecul
show
high
activ
vitro
would
reach
clinic
phase
due
lack
intestin
absorpt
andor
poor
vivo
metabol
stabil
tissu
distribut
socal
adm
absorpt
distribut
metabol
excret
properti
summari
develop
novel
antimicrobi
drug
combin
chemic
biolog
industri
approach
order
design
activ
compound
valid
use
develop
clinic
use
de
clercq
ta
usual
compos
two
gene
toxin
gene
encod
toxin
protein
toxic
effect
cell
wherea
antitoxin
either
rna
protein
counteract
toxic
cognat
toxin
depend
mode
antitoxin
neutral
toxin
ta
group
five
type
far
type
antitoxin
antisens
rna
prevent
translat
toxin
protein
bind
complementari
toxin
mrna
ii
type
ii
antitoxin
protein
bind
toxin
protein
interact
ppi
iii
type
iii
antitoxin
mrna
interact
directli
toxin
protein
iv
type
iv
antitoxin
protein
interfer
bind
toxin
protein
cell
target
v
type
v
antitoxin
protein
cleav
specif
cognat
toxin
mrna
hay
van
melderen
masuda
et
al
wang
et
al
analys
potenti
use
type
ii
ta
antimicrobi
target
sinc
abund
better
studi
among
ta
mechan
action
gener
unveil
type
ii
ta
exhibit
typic
featur
fig
antitoxin
gene
usual
preced
toxin
gene
ii
gene
cotranscrib
promot
locat
upstream
antitoxin
gene
iii
translat
coupl
operon
neg
autoregul
antitoxin
upon
bind
oper
region
overlap
singl
promot
operon
wherea
toxin
act
effici
corepressor
antitoxin
protein
labil
suscept
degrad
host
proteas
toxin
protein
much
stabl
ratio
toxin
antitoxin
import
determin
stoichiometri
ta
protein
complex
also
regul
transcript
operon
antitoxin
replenish
shield
toxic
normal
condit
monti
et
al
cataudella
et
al
howev
certain
stress
circumst
nutrit
stress
colon
new
host
dnadamag
agent
etc
transcript
ta
trigger
labil
antitoxin
degrad
rapidli
unleash
toxin
protein
act
target
classif
type
ii
ta
pair
easi
task
toxin
homologu
share
sequenc
similar
pair
differ
antitoxin
littl
sequenc
similar
eg
ta
gene
encod
antitoxin
phd
famili
toxin
rele
famili
anantharaman
aravind
gradi
hay
hay
van
melderen
toxin
share
similar
structur
despit
notabl
sequenc
similar
bind
differ
target
eg
ccdb
bind
dna
gyras
kid
similar
structur
ccdb
cleav
free
mrna
hargreav
et
al
toxin
thought
belong
differ
famili
similar
mode
action
eg
pare
ccdb
act
dna
gyras
jiang
et
al
van
melderen
complic
pictur
toxin
might
one
target
instanc
toxin
mycobacterium
tuberculosi
cleav
free
mrna
sequenc
cleav
site
also
cleav
rrna
singl
sequenc
ribosom
site
contact
trna
ribosom
recycl
factor
zhu
et
al
schifano
et
al
thu
instead
classifi
ta
gene
pair
toxin
superfamili
tabl
antitoxin
superfamili
identifi
hay
van
melderen
lepla
et
al
base
sequenc
similar
howev
number
ta
gene
know
date
seem
still
actual
number
sberro
et
al
sever
mechan
action
differ
toxin
identifi
tabl
via
inhibit
replic
target
dna
gyras
eg
ccdb
pare
jiang
et
al
van
melderen
inhibit
peptidoglycan
synthesi
phosphoryl
peptidoglycan
precursor
uridin
diphosphatenacetylglucosamin
eg
zetapezt
mutschler
et
al
inhibit
translat
sever
altern
mechan
cleav
free
rna
eg
mazf
kidpemk
hica
mqsr
pimentel
madin
de
la
cuevamendez
nariya
inouy
et
al
yamaguchi
park
inouy
agarw
et
al
ii
cleav
translat
rna
eg
rele
yoeb
higb
yafo
christensen
et
al
hurley
woychik
zhang
inouy
zhang
yamaguchi
inouy
iii
cleav
trnafmet
anticodon
stemloop
eg
vapc
winther
gerd
iv
inhibit
aminoacyltrna
synthetas
eg
hipa
germain
et
al
v
phosphoryl
conserv
threonin
translat
elong
factor
eftu
eg
doc
castroroa
et
al
toxic
effect
could
bacteriostat
bactericid
depend
upon
type
toxin
time
exposur
nieto
et
al
ta
operon
resid
chromosom
plasmid
singl
multipl
copi
sever
instanc
also
found
within
horizont
mobil
element
like
pathogen
island
ice
integr
mobiliz
element
larg
superintegron
rowemagnu
et
al
szeker
et
al
wozniak
waldor
gerd
begin
discoveri
ta
plasmidencod
ta
believ
function
exert
postsegreg
kill
psk
daughter
cell
inherit
parent
taencod
plasmid
bravo
de
torrontegui
bravo
et
al
et
al
howev
addit
role
plasmidencod
ta
ccdf
transmiss
persist
factor
report
tripathi
et
al
indic
role
plasmidencod
ta
might
far
complex
envisag
hand
function
chromosom
encod
ta
even
debat
van
melderen
saavedra
de
bast
van
melderen
makarova
et
al
suggest
involv
least
follow
process
global
stress
respons
lead
inhibit
cell
growth
unfavour
condit
toxic
revers
normal
environ
restor
christensen
et
al
ii
bacteri
program
cell
death
ie
altruist
behaviour
cell
sacrific
releas
nutrient
benefit
sibl
commun
whole
nutrient
scarc
engelbergkulka
glaser
iii
antiaddict
modul
chromosom
encod
ta
protect
cell
psk
mediat
plasmidencod
ta
homologu
de
bast
mine
van
melderen
iv
persist
lead
inhibit
cell
growth
mediat
ta
reduc
suscept
cell
antibiot
gerd
maisonneuv
v
biofilm
format
ren
et
al
kim
et
al
kolodking
et
al
vi
mainten
bacteri
mobilom
stabil
dispens
chromosom
region
prevent
extens
genet
loss
rowemagnu
et
al
szeker
et
al
vii
increas
surviv
rate
virul
ren
walker
dain
viii
colon
nich
norton
mulvey
employ
toxin
ta
use
number
biotechnolog
applic
propos
sever
case
success
develop
commerci
purpos
posit
select
plasmid
vector
stieber
gabant
szpirer
instanc
escherichia
coli
strain
harbour
plasmid
vector
express
lethal
toxin
gene
product
counteract
express
cognat
antitoxin
tran
clone
gene
achiev
transform
strain
devoid
antitoxin
thu
allow
select
recombin
inactiv
toxin
gene
recov
bernard
et
al
applic
ta
includ
control
releas
genet
modifi
organ
biospher
balanc
benefit
versu
possibl
risk
tackl
creat
genet
trap
term
activ
contain
system
avoid
bacteri
escap
base
control
express
lethal
gene
would
turn
case
escap
environ
toxin
broad
spectrum
mazf
kid
chosen
good
candid
genet
trap
ramo
et
al
guan
et
al
case
combin
two
toxin
act
differ
target
control
differ
regulatori
signal
consid
best
altern
risk
escap
contain
condit
estim
lower
torr
et
al
applic
biosensor
bioremedi
geneguard
system
develop
within
synthet
biolog
framework
use
varieti
bacteria
wright
et
al
food
industri
employ
ta
construct
plasmid
vector
number
plasmidfre
cell
decreas
well
vector
overproduc
plasmidencod
protein
absenc
antibiot
select
prove
use
approach
pecota
et
al
excel
review
biotechnolog
applic
ta
publish
suzuki
et
al
inouy
stieber
gabant
szpirer
unterholzn
poppenberg
rozhon
among
antiinfect
drug
recent
approv
clinic
use
antivir
agent
numer
follow
parallel
path
set
past
antibiot
antivir
licens
half
use
treatment
hiv
infect
antivir
licens
treatment
infect
herp
viru
hepat
b
c
influenza
de
clercq
even
viral
infect
alreadi
control
therapeut
modal
search
addit
molecular
target
new
treatment
strategi
still
follow
within
context
ta
offer
probabl
promis
solut
mazef
wellstudi
ta
operon
constitut
attract
candid
antivir
mention
mazf
toxin
endoribonucleas
preferenti
cleav
singlestrand
rna
c
residu
aca
recognit
sequenc
manner
independ
ribosom
thu
inhibit
protein
synthesi
zhang
et
al
wherea
maze
cognat
antitoxin
nullifi
mazf
toxic
far
awar
report
possibl
use
mazef
antivir
summar
fig
first
report
contempl
hivencod
transactiv
transcript
tat
protein
earli
viral
regul
possibl
target
chono
et
al
b
tat
produc
earli
infect
bind
transactiv
respons
tar
sequenc
induc
subsequ
express
protein
thu
tatdepend
mazf
express
system
retrovir
vector
construct
mazf
gene
insert
downstream
tar
sequenc
fig
consequ
mazf
express
viral
tat
protein
produc
cleav
mrna
specif
aca
codon
infect
cell
mazf
gene
contain
nine
aca
sequenc
engin
avoid
selfcleavag
without
alter
amino
acid
sequenc
maintain
toxic
hand
hiv
rna
contain
aca
sequenc
thu
viral
rna
hardli
escap
mazf
attack
experi
conduct
transduc
recombin
plasmid
human
lymphoid
line
cemss
cell
highli
suscept
hiv
infect
strikingli
transduc
cell
infect
iiib
replic
infect
viru
inhibit
level
also
affect
depict
fig
addit
level
mazf
induc
enough
caus
seriou
cell
damag
thu
maintain
normal
cell
growth
similar
result
observ
tatdepend
mazf
system
investig
rhesu
macaqu
primari
cell
monkey
infect
chimer
viru
shiv
chono
et
al
b
anoth
line
work
made
use
typifi
characterist
viral
proteas
specif
cleavag
site
target
explicitli
infect
cell
instead
innoc
one
park
yamaguchi
inouy
nonstructur
serin
proteas
hcv
protein
essenti
hcv
replic
mazf
system
construct
proteas
cleavag
site
linker
fuse
mazf
truncat
ctermin
maze
interpret
fig
fusion
protein
inert
incub
proteas
mazf
toxin
could
activ
via
cleavag
linker
maze
mazf
complex
park
yamaguchi
inouy
viral
proteas
cleavag
site
work
correspond
proteas
eg
proteas
factor
xa
park
yamaguchi
inouy
similar
construct
done
anoth
group
term
zymoxin
shapira
et
al
construct
activ
proteas
trex
cell
harbour
tetracyclineinduc
construct
activ
mazf
inhibit
cellular
protein
synthesi
observ
howev
cytotox
effect
also
evid
even
mildli
induc
shapira
et
al
possibl
undesir
effect
mazf
cleav
eukaryot
mrna
could
avoid
care
control
dosag
toxin
mazf
abl
cleav
viral
damag
cell
chono
et
al
b
one
challeng
aspect
drug
discoveri
find
novel
chemic
biolog
molecul
may
act
antibacteri
discoveri
pipelin
includ
new
natur
product
product
result
new
biosynthet
pathway
eg
molecul
control
cell
commun
although
also
may
includ
novel
chemic
molecul
antibacteri
proteinpeptid
potenti
target
develop
novel
antibacteri
could
make
use
toxin
bacteri
ta
gene
partli
wide
distribut
bacteria
archaea
eukaryot
cell
inouy
alonso
et
al
hay
makarova
et
al
mutschler
meinhart
chan
et
al
toxin
homologu
also
identifi
silico
fungi
function
experiment
valid
also
unknown
whether
cognat
antitoxin
present
oblig
intracellular
organ
propos
devoid
less
ta
cassett
contrast
freeliv
slow
grow
prokaryot
mani
ta
cassett
pandey
gerd
recent
analys
howev
confirm
observ
lepla
et
al
interestingli
comparison
genom
danger
epidem
bacteria
close
relat
nonepidem
speci
show
ta
could
particip
virul
repertoir
georgiad
raoult
georgiad
compar
genom
studi
show
presenc
ta
modul
significantli
associ
pathogen
bacteria
de
la
cruz
et
al
exampl
tuberculosi
contain
least
function
ta
gene
put
ta
gene
pair
test
ramag
connolli
cox
wherea
nonpathogen
counterpart
smegmati
three
function
ta
gene
robson
et
al
mckenzi
et
al
furthermor
number
ta
gene
report
far
seriou
underestim
real
figur
microbi
world
thorough
way
identifi
function
ta
gene
instead
silico
screen
done
via
shotgun
clone
reveal
mani
toxin
gene
could
clone
neighbour
antitoxin
gene
present
sberro
et
al
situat
could
complex
exemplifi
possibl
type
ii
ta
present
chromosom
pathogen
bacterium
streptococcu
pneumonia
bioinformat
approach
predict
exist
differ
put
ta
chan
et
al
howev
genet
physiolog
valid
candid
show
four
predict
operon
bona
fide
function
ta
even
though
put
toxin
gene
exhibit
toxic
overexpress
cognat
gene
pair
counteract
toxic
respect
thu
rule
classic
ta
chan
et
al
presenc
one
copi
ta
may
sourc
uncertainti
close
relat
antitoxin
may
function
interact
paradigm
one
toxin
may
correct
zhu
et
al
could
thought
crosstalk
chromosom
encod
toxin
antitoxin
exist
perhap
mean
adapt
bacteria
environment
chang
popul
encount
along
colonizationinvas
new
nich
zhu
et
al
inde
case
scenario
would
much
complex
envisag
taken
togeth
featur
make
exploit
ta
antibacteri
major
challeng
due
redund
target
valid
well
specif
select
offtarget
activ
drug
candid
target
specif
ta
would
difficult
assess
despit
toxin
ta
pair
could
attract
antibacteri
target
use
standalon
drug
combin
classic
antibiot
mutschler
meinhart
park
mann
li
unterholzn
poppenberg
rozhon
howev
seem
combin
current
approv
antibiot
would
least
present
anoth
major
challeng
term
match
formul
gener
combin
product
rout
approach
problem
vari
depend
upon
way
toxin
effect
envisag
first
place
toxin
go
candid
fact
ta
absent
human
irrelev
toxin
ta
pair
novel
target
consid
drug
discoveri
must
compli
set
requir
lack
toxic
eukaryot
cell
target
infect
bacteria
howev
toxin
ta
gene
also
harm
human
cell
unless
care
monitor
toxin
dosag
mention
antivir
test
safe
deliveri
system
appli
addit
provis
replenish
commens
flora
howev
ta
go
use
target
drug
ligand
argument
relev
keep
mind
challeng
relat
redund
sever
strategi
disrupt
interfac
antitoxin
cognat
toxin
inhibitor
ppi
envisag
well
possibl
use
toxin
combin
strategi
alonso
et
al
mutschler
meinhart
summar
report
studi
well
view
whether
employ
ta
could
consid
promis
candid
futur
use
biopharmaceut
industri
also
discuss
pro
con
use
toxin
druggabl
antimicrobi
target
known
toxin
ta
act
endoribonucleas
cleav
mrna
associ
translat
ribosom
independ
mrna
origin
prokaryot
eukaryot
thu
toxin
could
act
antitumour
agent
fact
propos
kid
toxin
plasmid
could
use
effici
anticanc
compound
de
la
cueva
et
al
one
approach
could
use
tumourspecif
promot
direct
therapeut
express
toxin
cancer
cell
yang
et
al
recent
revers
induc
solid
tumour
mice
report
employ
engin
version
mazf
toxin
nevertheless
rate
success
revers
around
probabl
due
loss
function
toxin
shimazu
et
al
loss
activ
observ
toxin
vapc
tuberculosi
pasb
plasmid
thiobacillu
ferrooxidan
express
human
cancer
cell
wieteska
et
al
find
leav
door
open
test
thoroughli
possibl
employ
toxin
tumour
cell
howev
light
possibl
use
toxin
antibacteri
import
consid
toxin
deliv
directli
patient
kill
pathogen
advers
effect
toxin
normal
commens
flora
human
cell
could
also
difficult
avoid
perhap
shown
antivir
activ
mazf
interferas
dosag
toxin
critic
factor
test
activ
eukaryot
cell
chono
et
al
b
effici
approach
would
includ
specif
target
pathogen
bacteria
harbour
ta
trigger
releas
toxin
found
human
cell
toxin
bactericid
ideal
antibacteri
infect
bacteria
would
kill
toxin
zielenkiewicz
ceglowski
mutschler
meinhart
howev
stasi
dormanc
due
tempor
reduct
cell
growth
common
effect
toxin
bacteriostat
effect
revers
induct
antitoxin
pedersen
christensen
gerd
maisonneuv
et
al
germain
et
al
recoveri
dormanc
due
toxin
may
effect
given
time
period
prolong
exposur
bacteria
toxin
like
rele
lead
cell
lethal
nieto
et
al
addit
also
factor
consid
toxin
alon
one
administ
sinc
instanc
toxin
may
differ
panorama
toxic
differ
host
eg
express
toxin
zeta
plasmid
discov
pyogen
bactericid
gramposit
bacillu
subtili
bacteriostat
gramneg
e
coli
zielenkiewicz
ceglowski
first
gene
discov
involv
persist
hipa
e
coli
also
toxin
gene
hipba
ta
pair
moy
bertrand
toxin
hipa
inhibit
aminoacyl
counteract
cognat
antitoxin
hipb
turn
degrad
lon
proteas
gerd
christensen
lobnerolensen
schumach
et
al
hansen
et
al
germain
et
al
upon
exposur
ampicillin
wildtyp
strain
show
persist
cell
ratio
howev
doubl
mutant
hipa
allel
abolish
toxic
hipa
show
increas
frequenc
persist
ratio
experiment
condit
moy
bertrand
overexpress
wildtyp
hipa
also
increas
frequenc
persist
level
confer
allel
korch
hill
hipa
toxin
shown
phophoryl
near
activ
centr
trnaglubound
glutamyltrna
synthetas
thu
accumul
uncharg
trnaglu
germain
et
al
find
taken
indic
enter
uncharg
trnaglu
site
ribosom
would
trigger
activ
releas
rela
alarmon
pentaphosph
pppgpp
synthetas
turn
would
lead
dramat
increas
pppgpp
whose
level
posit
correl
persist
level
germain
et
al
maisonneuv
castrocamargo
gerd
anoth
studi
group
format
persist
shown
modul
signal
nucleotid
pppgpp
cascad
involv
inorgan
polyphosph
polyp
long
linear
polym
orthophosph
residu
lon
proteas
ta
concentr
polyp
control
pppgpp
competit
inhibit
exopolyphosphatas
degrad
polyp
polyp
demonstr
stimul
lonmedi
degrad
antitoxin
ta
pair
stochast
small
subpopul
cell
would
lead
releas
toxin
eventu
would
promot
inhibit
cellular
biosynthesi
cessat
cell
growth
persist
maisonneuv
castrocamargo
gerd
previou
studi
show
prolong
exposur
antibiot
activ
transcript
ta
encod
mrnase
e
coli
activ
led
inhibit
global
cellular
translat
render
cell
state
dormanc
persist
singl
delet
toxin
mrnase
affect
persist
format
requir
delet
ta
encod
mrnase
cumul
reduc
level
persist
maisonneuv
et
al
redund
ta
increas
frequenc
persist
cell
stochast
fluctuat
spontan
switch
ta
give
rise
bistabl
state
normal
cell
persist
fasani
savageau
ta
also
shown
influenc
biofilm
format
certain
instanc
delet
ta
loci
decreas
biofilm
format
kim
et
al
kolodking
et
al
wen
behiel
devrees
coincid
instanc
sever
ta
upregul
biofilmform
cell
mitchel
et
al
mechan
involv
still
well
understood
perhap
direct
evid
involv
ta
biofilm
format
albeit
differ
pathway
case
antitoxin
mqsa
ta
loci
mqsa
serv
global
regul
repress
express
csgd
master
regul
biofilm
format
repress
csgd
msqa
lead
reduct
signal
nucleotid
cdigmp
curli
product
therebi
reduct
biofilm
format
harrison
et
al
soo
wood
persist
pose
signific
challeng
treatment
bacteri
infect
latent
infect
posttreat
relaps
biofilm
also
rais
problem
form
host
surviv
persist
lewi
zhang
et
al
know
activ
ta
increas
persist
common
antibiot
kill
grow
bacteria
could
conjectur
turn
risk
opportun
reduc
bacteri
cell
growth
increas
persist
cell
format
activ
ta
treat
persist
cell
persist
druglik
pza
pza
unconvent
persist
drug
tuberculosi
act
nongrow
persist
cell
acid
condit
shorten
tuberculosi
treatment
period
month
month
kill
subpopul
persist
kill
tuberculosi
drug
zhang
et
al
consequ
line
develop
ta
antibacteri
new
drug
target
persist
also
develop
approach
deal
persist
could
wake
persist
enhanc
activ
antibiot
har
host
immun
system
review
zhang
et
al
one
propos
approach
druggabl
bacteri
toxin
identifi
peptid
small
molecul
abl
disrupt
protein
antitoxin
toxin
interact
base
bind
interfac
ppiapproach
et
al
bind
affin
ta
pair
vari
make
difficult
estim
dosag
inhibitor
instanc
pezat
pair
exhibit
strong
bind
affin
bind
constant
femtomolar
rang
three
eight
order
magnitud
higher
ta
phddoc
relb
ccdab
even
homologu
pezat
gazit
sauer
camacho
et
al
daothi
et
al
overgaard
borch
gerd
mutschler
reinstein
meinhart
even
though
ppi
interfac
interest
target
develop
novel
molecul
still
promis
exampl
drug
design
ta
interfac
use
highthroughput
screen
techniqu
identifi
hit
act
ippi
conjunct
develop
techniqu
optim
possibl
hit
discov
proper
lead
hittolead
techniqu
matter
fulli
solv
yet
specif
bioluminisc
reson
energi
transfer
bret
assay
xu
piston
johnson
test
librari
peptid
could
disrupt
interfac
develop
nieto
et
al
tool
vivo
assay
amen
highthroughput
scale
clear
advantag
fluoresc
reson
energi
transfer
fret
base
assay
bret
suscept
photobleach
thu
yield
reliabl
result
bret
proven
construct
tool
identifi
potenti
hit
interrupt
fig
lioy
et
al
studi
sever
librari
encompass
variou
million
peptid
use
attempt
disrupt
ta
protein
complex
two
posit
aminoacidlong
hit
found
two
sublibrari
howev
new
record
progress
report
lioy
et
al
also
remain
unknown
whether
peptid
bind
antitoxin
toxin
besid
disrupt
interfac
protein
import
ensur
bind
peptid
toxin
hinder
catalyt
activ
toxin
releas
toxin
still
act
target
kill
pathogen
shown
anoth
studi
peptid
design
base
antitoxin
sequenc
abl
disrupt
interfac
toxic
toxin
also
reduc
agarw
et
al
suggest
peptid
design
base
toxin
sequenc
bind
antitoxin
would
better
approach
employ
peptid
size
rang
amino
acid
tackl
disrupt
ppi
import
advantag
high
specif
potenti
lower
failur
rate
inclus
drug
pipelin
clinic
trial
howev
biolog
molecul
shown
sever
shortcom
poor
oral
avail
high
cost
bioprocess
altern
tradit
highthroughput
screen
librari
fragmentbas
method
drug
discoveri
erlanson
mcdowel
brien
emerg
stun
approach
mainstream
discoveri
new
drug
within
pharmaceut
compani
mani
academ
group
fig
comparison
put
candid
novel
drug
indic
drug
deriv
fragmentbas
screen
could
uncov
novel
compound
druglik
properti
deriv
convent
drug
discoveri
techniqu
search
fragment
driven
rule
three
molecular
mass
da
number
hydrogen
bond
donor
acceptor
clogp
congrev
et
al
fragmentbas
lead
discoveri
deal
low
molecular
mass
low
affin
molecul
later
optim
drug
lead
park
mann
li
fragmentbas
approach
success
sinc
allow
market
drug
vemurafenib
drug
metastat
melanoma
six
year
baker
addit
sever
group
uk
join
develop
fragment
consortium
http
devot
build
share
librari
fragment
enhanc
three
dimension
compound
seem
advantag
tradit
approach
new
technolog
aim
character
contact
surfac
two
interact
protein
conjunct
methodolog
base
structurebas
design
facilit
detect
small
molecul
act
ippi
identif
compound
may
act
ippi
seem
attain
comput
drug
design
bienstock
number
strategi
employ
check
hotspot
region
interfac
protein
crystallographi
elucid
protein
structur
molecular
dock
virtual
screen
approach
design
novel
drug
librari
review
depth
bienstock
huang
although
strong
need
curat
databas
help
discoveri
ppimodul
see
instanc
http
develop
novel
databas
assist
find
design
novel
ippi
prove
use
purpos
et
al
number
ta
structur
solv
would
lead
thorough
approach
find
small
molecul
abl
disrupt
interact
design
custom
sinc
hydrophob
residu
seem
domin
interfac
toxin
cognat
antitoxin
lori
et
al
hargreav
et
al
kamada
hanaoka
burley
takagi
et
al
kamphui
et
al
ober
et
al
kumar
et
al
brown
et
al
francuski
saenger
miallau
et
al
arb
et
al
dienemann
et
al
et
al
heaton
et
al
kwon
et
al
feng
et
al
samson
et
al
schureck
et
al
structur
knowledg
ta
enabl
us
get
better
understand
surfac
contact
two
protein
pair
develop
inhibitor
facilit
park
mann
li
approach
could
refin
employ
select
databas
dedic
ppi
alreadi
known
inhibitor
small
molecul
taken
exampl
construct
guidelin
character
ippi
http
number
differ
strategi
suggest
possibl
mean
druggabl
toxin
mutschler
meinhart
chan
et
al
gerd
unterholzn
poppenberg
rozhon
strategi
base
find
antitoxin
suscept
degrad
host
proteas
cognat
toxin
therefor
inhibit
replenish
antitoxin
toxin
releas
exhibit
toxic
cell
cognat
antitoxin
degrad
conceiv
number
strategi
pro
con
schemat
fig
firstli
one
approach
could
inhibit
transcript
ta
pair
autoregul
would
take
place
synthesi
ta
would
hinder
use
differ
halfliv
two
protein
likelihood
degrad
antitoxin
releas
toxin
could
increas
achiev
goal
one
possibl
could
use
mutant
antitoxin
enhanc
dna
bind
affin
superrepressor
devoid
abil
complex
cognat
toxin
could
achiev
usual
bind
site
antitoxin
dna
ntermin
moieti
wherea
cognat
toxin
cterminu
perhap
challeng
would
bind
affin
antitoxin
gener
weak
repressor
except
report
case
ta
pair
e
coli
brown
et
al
pard
plasmid
davi
helinski
robert
ober
et
al
character
featur
could
easili
follow
novel
techniqu
base
differenti
repress
green
fluoresc
protein
express
chan
et
al
secondli
could
envisag
inhibit
translat
antitoxin
antisens
molecul
even
though
ta
gene
cotranscrib
singl
mrna
transcript
toxin
gene
usual
carri
sequenc
embed
within
upstream
antitoxin
gene
chan
et
al
thu
antisens
rna
silenc
antitoxin
could
achiev
bind
short
rna
sequenc
specif
oligonucleotid
antitoxin
code
region
initi
translat
signal
antitoxin
without
affect
translat
toxin
howev
factor
consid
effici
antisens
bind
mrna
length
antisens
molecul
possibl
interfer
translat
toxin
protein
stabil
antisens
molecul
ie
degrad
bacteri
rnase
also
doublestrand
natur
gener
rna
bind
mrna
target
antisens
antibacteri
strategi
develop
sinc
two
decad
ago
continu
refin
antisens
oligodeoxynucleotid
asodn
silenc
essenti
gene
mrnadna
level
unmodifi
rnadna
labil
prone
degrad
nucleas
addit
exhibit
poor
pharmacokinet
properti
whole
plethora
asodn
develop
improv
stabil
intrins
affin
target
mainli
via
modif
backbon
phosphodiest
bond
sugar
ring
exampl
asodn
deriv
includ
phosphorothio
oligodeoxyribonucleotid
psodn
first
gener
oligonucleotid
second
gener
lock
nucleic
acid
phosphorodiamid
morpholino
oligonucleotid
pmo
thiophosphoroamid
oligonucleotid
peptid
nucleic
acid
pna
third
gener
bai
luo
among
molecul
pna
pmo
gone
preclin
clinic
evalu
prove
promis
antisens
drug
bai
luo
nielsen
egholm
pna
molecul
synthet
analogu
nucleic
acid
phosphatesugar
backbon
replac
flexibl
pseudopeptid
polym
base
attach
thu
pna
mimic
pair
dna
rna
gener
duplex
resist
enzymat
degrad
although
pna
proven
good
silenc
deliveri
would
one
major
challeng
easi
tackl
ray
coupl
antisens
molecul
modifi
peptid
call
membranepenetr
peptid
explor
use
antibacteri
one
fascin
exampl
peptideconjug
pmo
compound
synthet
oligom
mimick
nucleic
acid
structur
one
end
attach
short
peptid
peptid
design
repeat
sequenc
cation
nonpolar
amino
acid
residu
facilit
oligom
penetr
gramneg
outer
membran
conjug
compound
target
silenc
specif
gene
shown
activ
antibacteri
geller
et
al
third
approach
could
target
proteas
cleav
antitoxin
appear
either
lon
clpp
van
melderen
et
al
christensen
et
al
although
may
yet
identifi
proteas
induct
proteas
would
lead
antitoxin
degrad
releas
cognat
toxin
activ
proteas
degrad
antitoxin
lead
kill
bacteri
persist
freed
toxin
william
hergenroth
approach
combin
antibiot
result
biofilm
erad
vitro
consid
could
novel
avenu
treatment
chronic
infecti
diseas
conlon
et
al
like
endocard
bronchiti
otiti
etc
tackl
diseas
deriv
infect
intern
prosthesi
catheterrel
intervent
http
anoth
interest
strategi
develop
mazef
ta
widespread
ta
among
mani
bacteria
mani
pathogen
propos
kumar
engelbergkulka
involv
trigger
ta
outsid
extracellular
death
factor
edf
short
peptid
act
quorum
sensor
although
edf
speciesspecif
seem
provok
trigger
mazef
heterolog
host
pseudomona
aeruginosa
b
subtili
edf
activ
e
coli
mazef
lead
death
latter
bacteri
cell
kumar
kolodking
engelbergkulka
clever
strategi
might
enough
start
point
develop
novel
antibacteri
howev
would
activ
particular
ta
kumar
engelbergkulka
last
least
sinc
differ
ta
differ
target
select
kind
ta
could
altern
explor
combin
use
ta
target
cell
wall
eg
pezat
target
mrna
mazef
could
lead
antibacteri
broad
spectrum
howev
even
approach
could
follow
merit
thorough
experiment
explor
believ
would
confront
major
problem
deliveri
strategi
one
hurdl
overcom
design
new
drug
deliv
appropri
tissu
target
research
drug
deliveri
multidisciplinari
requir
knowledg
drug
work
ii
chemic
physic
properti
iii
properti
affect
vivo
behaviour
drug
iv
drug
reach
target
vi
could
done
formul
drug
potenti
solv
deliveri
problem
associ
therefor
drug
deliveri
research
necessit
interdisciplinari
collabor
nation
intern
level
although
rang
deliveri
system
avail
deliveri
sensit
drug
peptid
nucleic
acidbas
therapeut
includ
antisens
rna
small
interf
rna
simpl
complex
carbohydr
synthet
vaccin
present
major
challeng
pharmaceut
industri
formul
novel
molecul
drug
deliveri
costli
sinc
nearli
cost
drug
develop
devot
area
allen
culli
abovement
biolog
could
formul
way
expens
inconveni
instanc
replac
powder
readytous
liquid
may
import
improv
storag
materi
cold
versu
shelf
storag
may
constitut
import
bia
employ
protein
improv
heat
stabil
lead
simpler
transport
distribut
process
new
develop
drug
deliveri
research
like
enorm
econom
impact
upon
pharmaceut
biotechnolog
industri
fact
drug
deliveri
research
repres
us
billion
year
industri
centr
drug
deliveri
formul
establish
world
promot
research
develop
train
drug
deliveri
scienc
also
focu
realiz
commerci
potenti
innov
molecul
eg
peptid
nucleic
acid
base
therapi
vaccin
deliveri
technolog
develop
basic
research
centr
thu
wonder
number
novel
clever
approach
propos
deliv
new
drug
case
bacteri
toxin
go
develop
antimicrobi
one
interest
system
albeit
still
hypothet
could
employ
bacteri
minicel
deliveri
fig
de
la
minicel
produc
bacteria
defect
cell
divis
lack
chromosom
dna
plasmid
segreg
continu
metabol
activ
thu
earli
shown
mani
laboratori
among
espinosa
lopez
lack
lack
et
al
plasmid
minicel
abl
synthes
de
novo
product
encod
includ
ta
protein
shown
pair
bravo
de
torrontegui
bravo
et
al
plasmid
encod
desir
ta
construct
segreg
minicel
make
good
deliveri
candid
target
cell
macdiarmid
et
al
must
remark
minicel
seem
appropri
enough
treatment
bacteri
infect
minicel
engulf
prokaryot
cell
could
envisag
howev
use
deliveri
solut
treatment
cancer
cell
macdiarmid
et
al
de
la
anoth
interest
deliveri
approach
make
use
cellpenetr
peptid
cpp
carrier
peptid
sebbag
cpp
peptid
amino
acid
intern
energyfre
mechan
well
understood
yet
cpp
shown
readili
intern
mammalian
cell
effect
carrier
drug
develop
zorko
langel
howev
cpp
approach
would
seem
appropri
use
toxin
antivir
chono
et
al
b
antibacteri
peptid
would
overcom
barrier
offer
bacteri
cell
wall
could
imagin
coupl
toxin
microcin
peptid
eg
lasso
peptid
rebuffat
penetr
bacteri
cell
wall
might
offer
altern
employ
cpp
novel
approach
yet
fulli
develop
carrier
constitut
carbon
nanotub
cnt
nanomolecul
made
layer
graphen
dispos
layer
built
needleshap
cylind
bai
luo
cnt
use
inject
plasmid
dna
e
coli
cell
rojaschapana
et
al
cnt
approach
use
carrier
deliveri
antimicrobi
although
use
anticanc
drug
advanc
drug
therapi
review
wong
et
al
howev
far
seem
cytotox
molecul
patient
overcom
perhap
eleg
strategi
limit
speciesspecif
would
use
recombin
bacteriophag
defect
lysi
harbour
desir
toxin
gene
clone
control
earli
usual
strong
promot
upon
inject
phage
dna
toxin
gene
transcrib
translat
releas
toxin
kill
pathogen
huy
et
al
samson
et
al
present
number
plausibl
sometim
specul
approach
tackl
druggabl
ta
also
tri
discuss
differ
angl
subject
well
present
thoughtprovok
manner
fortun
increas
number
protein
ta
structur
solv
facilit
studi
ta
interfac
turn
permit
perform
silico
dock
experi
design
molecul
may
disrupt
interact
opinion
fragmentbas
drug
design
deal
disrupt
ta
interact
seem
one
like
approach
develop
ta
good
candid
enter
antibacteri
pipelin
perhap
use
approach
would
rational
design
fragment
librari
base
known
structur
ta
solv
far
park
sj
et
al
ii
employ
fragment
design
bind
ctermin
moieti
antitoxin
seem
less
structur
ntermin
domain
appropri
chemic
space
two
protein
excit
altern
explor
employ
antisens
small
rna
molecul
inhibit
translat
operon
ji
et
al
faridani
et
al
makarova
grishin
koonin
kawano
aravind
storz
mruk
kobayashi
combin
appropri
deliveri
system
perhap
engin
bacteriophag
peptid
howev
good
proof
principl
druggabl
ta
protein
effect
antibacteri
approach
could
envisag
one
would
diagnos
first
sever
ta
encod
infect
bacterium
pcr
amplif
use
set
specif
oligonucleotid
per
ta
pair
identif
set
ta
could
easili
achiev
enter
appropri
databas
like
instanc
tadb
http
bioinfommlsjtueducntadb
could
follow
administr
indic
drug
identifi
infect
agent
rather
random
drug
use
perhap
abus
believ
research
new
antibacteri
meet
need
daytoday
clinician
work
hospit
fast
respons
grant
within
easi
technolog
access
userfriendli
databas
could
conceiv
scenario
novel
avenu
open
explor
real
novel
drug
